Nemes Laszlo
- Lakefront Biotherapeutics (LKFT) has completed the sale of its pre-clinical CAR-T programs for cancer to Armed Cell Therapeutics.
- The assets include “multi-targeting and armed CAR-T constructs designed to improve the potency and persistence of CAR-Ts and prevent cancer treatment
